INSM
Insmed Incorporated
NASDAQ · USHealthcareBiotechnology
$107.02-1.20%
Price as of Jul 20, 2026
INSM financials
Insmed Incorporated financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $606.4M | $363.7M | $305.2M | $245.4M |
| Cost of revenue | $124.9M | $85.7M | $65.6M | $55.1M |
| Gross profit | $481.5M | $278.0M | $239.6M | $190.2M |
| Operating expenses | $1.7B | $1.2B | $949.3M | $647.6M |
| Operating income | -$1.2B | -$878.3M | -$709.6M | -$457.3M |
| Net income | -$1.3B | -$913.8M | -$749.6M | -$481.5M |
| EBITDA | -$1.2B | -$818.8M | -$660.2M | -$447.4M |
| Basic EPS | $-6.41 | $-5.57 | $-5.34 | $-3.91 |
| Diluted EPS | $-6.41 | $-5.57 | $-5.34 | $-3.91 |
| Balance sheet | ||||
| Cash & equivalents | $510.4M | $555.0M | $482.4M | $1.1B |
| Total assets | $2.3B | $2.0B | $1.3B | $1.7B |
| Total liabilities | $1.5B | $1.7B | $1.7B | $1.6B |
| Stockholders’ equity | $739.0M | $285.4M | -$331.9M | $88.0M |
| Total debt | $768.2M | $1.3B | $1.2B | $1.2B |
| Net debt | $257.7M | $759.1M | $721.6M | $103.8M |
| Cash flow | ||||
| Operating cash flow | -$935.0M | -$683.9M | -$536.2M | -$400.4M |
| Capital expenditure | -$32.6M | -$21.9M | -$13.3M | -$9.9M |
| Free cash flow | -$967.6M | -$705.8M | -$549.5M | -$410.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |